Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting
- Interim Results of the Phase 1 AURELIO-03 study of SOT101 in combination with pembrolizumab for patients with advanced metastatic tumors were presented at the 2022 AACR Annual Meeting
- Data demonstrates that SOT101 in combination with pembrolizumab was well tolerated and the majority of patients had clinical benefit
- Additional posters outline preclinical findings on immunocytokine, SOT201, and lead BOXR CAR-T platform candidate, BOXR1030
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced interim safety and efficacy results from the ongoing Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, in combination with pembrolizumab in patients with advanced/metastatic solid tumors. The data were presented by Dr. Stephane Champiat from Gustave Roussy Cancer Center in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022. The company also presented findings from preclinical studies of its immunocytokine candidate SOT201, and of its CAR-T cancer therapy BOXR1030 in two poster presentations at the meeting.
SOTIO Announces Oral and Multiple Poster Presentations on Key Clinical Programs at the American Association of Cancer Research Annual Meeting (AACR) 2022
- Oral presentation will focus on interim efficacy and safety data from the Phase 1/1b AURELIO-03 study of SOT101 in combination with pembrolizumab
- Poster presentations will feature preclinical data on SOTIO’s immunocytokine SOT201 and the BOXR CAR-T cell therapy BOXR1030
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will deliver an oral presentation featuring interim safety and efficacy data from its Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, in combination with pembrolizumab, as well as two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022.
SOTIO Announces Clinical Collaboration with MSD to evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
- The Phase 2 AURELIO-04 study is expected to enroll up to 300 patients across six different indications
- The study will be conducted in the US and selected European countries and will begin in the first half of 2022
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 AURELIO-04 study.
SOTIO Biotech B.V.
Strawinskylaan 933
1077XX Amsterdam
Netherlands
Strawinskylaan 933
1077XX Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
Term of use
Data protection
Cookies Policy
Cookie settings
Clinical Trials Privacy Notice
© 2013 - 2024 Sotio
Sitemap
Terms of Use and Privacy
© 2013 - 2024 Sotio